Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | LPL | P06858 | 1/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659527 | 0.88 | MAOB (0.57) | MAOBDGAT1NR4A2MAOALPL | |
| SCHEMBL20361020 | 0.87 | LIPG (0.48) | MAOBDGAT1LPLLIPG | |
| SCHEMBL16795672 | 0.87 | LPL (0.51) | MAOBDGAT1NR4A2PARP10LPL | |
| SCHEMBL16795684 | 0.86 | MAOB (0.53) | MAOBDGAT1NR4A2MAOALPL | |
| SCHEMBL257883 | 0.85 | DGAT1 (0.55) | MAOBDGAT1OPRM1OPRD1MAOA | |
| SCHEMBL19000514 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPG | |
| SCHEMBL17129418 | 0.84 | MAOB (0.58) | MAOBDGAT1FFAR1ACHE | |
| SCHEMBL17129613 | 0.84 | MAOB (0.59) | MAOBDGAT1NR4A2MAOAFFAR1 | |
| SCHEMBL21568905 | 0.83 | LPL (0.59) | MAOBDGAT1NR4A2PARP10LPL | |
| SCHEMBL298401 | 0.83 | DGAT1 (0.72) | MAOBDGAT1NR4A2MAOALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124534-B | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application | 中山大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-115124534-A | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application | 中山大学 | 2022-09-30 | — | — | CN | disclosed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | MAOB 3018/4885DGAT1 2399/4885NR4A2 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.